Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




Virtify’s Content-Centric Solutions Build Efficiency by Repurposing Data



By Ann Neuer

August 24, 2009 | Smart life sciences companies anxious to compress clinical development timelines are moving from a document-centric workflow to a content-centric environment. So says Stephen Bergson, executive vice president, commercial operations of Virtify, a provider of enterprise content compliance solutions.

Stephen_Bergson
Stephen Bergson
“The industry is realizing that document management systems produce static documents that are cumbersome and don’t allow for ready re-use. By moving to a content management environment, you can use, re-use and repurpose compliant content across the enterprise instead of developing the same information over and over again,” Bergson explains.

He is referring to the trend that along the continuum—from discovery to clinical trials to post-approval commercialization—sponsors are seeking to leverage content by intelligently tagging it and simply lifting it from a central data repository that is created throughout a product’s lifecycle. With that capability, data only has to be developed once and it can be re-used for any number of upstream and downstream purposes. For example, existing information can flow into structured product labeling (SPL) documents, electronic common technical documents (eCTD), and be extrapolated for manufacturing standard operating procedures (SOPs). In addition, if documents have changed since originally created, the user is notified of those changes, and only the latest versions are applied.

Being able to leverage content across the enterprise has real ramifications for speeding product development and cutting costs associated with pre- and post-marketing regulatory submissions. Research suggests that approximately 26% of the cost of bringing new drugs to market is linked to creating content in a compliant manner, so any effort to reduce that percentage will have a positive impact on the bottom line. Bergson remarks, “We believe that with effective re-use of compliant content, we can drop that figure by an order of magnitude.”

Mandates from various regulatory agencies across the globe and greater acceptance of standards are driving the move to compliant content-centric systems. Bergson points to factors such as Health Level 7 (HL7) standards, the Information Technology Plan in the Prescription Drug User Fee Act IV (PDUFA), and the European Medicines Agency’s (EMEA) mandatory use of the eCTD for submissions using the Centralised Procedure, starting January 2010. In addition, required adverse event reporting begins in September 2009, as stated in Section 801(a) of the Food and Drug Administration Amendments Act (FDAAA); and there is the upcoming regulated product submission standard.

To address this complex regulatory environment and to streamline re-use of content, Virtify recently launched Virtx, a Web-based, collaborative enterprise content compliance suite that the company claims is the industry’s first. Virtx offers end-to-end solutions through a series of modules that are out-of-the-box ready, but are also configurable. The Virtx modules include SPL, eCTD, Clinical Trial Disclosure System (CTDS), Upcoming Standards Support, and enterprise eCompliance products that automate collaborative document authoring, submissions tracking, and other functions. The suite has an extensible markup language (XML) backbone, uses Web 2.0 architecture and offers a user-friendly interface that is presented in a familiar Microsoft Word-like format.

With the September 27 start date for FDA’s required adverse event reporting on www.clinicaltrials.gov, and with the anticipation that other regulatory agencies will require this same function, there is particular interest in the Clinical Trial Disclosure System module. “CTDS is hot right now with all of the clinical trial mandates and directives coming from regulators,” Bergson comments.

Repurposing content takes the market in a promising direction. According to Bergson, “Clients are realizing that it is costing them a fortune to develop documents and then have them go into a static environment. With life science mandates extending out to 2015, and with new mandates being developed, transitioning out of a static-document world into a content-centric world is where the industry is going.”

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .